Latest Antimalarial drug Stories
Evidence that the most deadly species of malaria parasite, Plasmodium falciparum, is becoming resistant to the front line treatment for malaria on the border of Thailand and Myanmar (Burma) is reported in The Lancet today.
Emergence of resistance to the drug artemisinin in western Thailand has created a critical point in global efforts to control and eliminate malaria worldwide.
Malaria infections among infants can be cut by up to 30 per cent when antimalarial drugs are given intermittently over a 12 month period, a three-year clinical trial in Papua New Guinea has shown.
Malaria continues to be a major disease worldwide, but while funding projects are working hard to improve malaria prevention it is difficult to measure how effective these interventions are.
A three-arm randomized trial conducted by Ivo Mueller of the Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea, and colleagues among infants in Papua New Guinea estimates the preventive effect against malaria episodes of intermittent preventive treatment, in an area where children are exposed to both falciparum and vivax malaria.
A chemically altered osteoporosis drug may be useful in fighting malaria, researchers report in a new study. Unlike similar compounds tested against other parasitic protozoa, the drug readily crosses into the red blood cells of malaria-infected mice and kills the malaria parasite.
In this week's PLoS Medicine, Michael Delves of Imperial College London, UK and colleagues compare the activity of 50 current and experimental antimalarials against liver, sexual blood, and mosquito stages of selected human and nonhuman parasite species, including Plasmodium falciparum, Plasmodium berghei, and Plasmodium yoelii.
A study of almost 3,800 pregnancies has provided the most accurate and direct evidence to date that malaria infection reduces early foetal growth.
New research by scientists at the University of Southampton could lead to the design of more effective drugs to combat malaria.
- A person in a secondary role, specifically the second most important character (after the protagonist).